Clinical trial
Safety and Effectiveness of an Investigational Agent (GM-611) in Patients With…
NCT00050882 · Chugai Pharma USA, Industry · Completed
Key facts
| NCT number | NCT00050882 |
|---|---|
| Title | Safety and Effectiveness of an Investigational Agent (GM-611) in Patients With Diabetic Gastroparesis |
| Official title | A 12-Week Study Conducted at Multiple Centers, Blinded to Both the Patient and Doctor, Evaluating for Safety and Effectiveness Two Dosages of an Investigational Agent (GM-611) Versus a Placebo, That Are Randomly Assigned to Patients With Diabetic Gastroparesis |
| Lead sponsor | Chugai Pharma USA, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastroparesis |
| Intervention type | Drug |
| Interventions | GM-611 |
| First posted | Dec 31, 2002 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: